Background and Purpose. The vasoconstrictor endothelin-1 (ET-1) has been implicated in the pathogenesis of cerebral vasospasm following subarachnoid hemorrhage (SAH). Previous results showed that CGS 26303, an endothelin converting enzyme (ECE) inhibitor, effectively prevented and reversed arterial narrowing in animal models of SAH. In the present study, we assessed the effect of CGS 26303 on neurological deficits in SAH rats. The involvement of vasoactive pathways downstream of ET-1 signaling in SAH was also investigated. Methods. Sprague-Dawley rats were divided into five groups ( = 6/group): (1) normal control, (2) SAH, (3) SAH+vehicle, (4) SAH+CGS 26303 (prevention), and (5) SAH+CGS 26303 (reversal). SAH was induced by injecting autologous blood into cisterna magna. CGS 26303 (10 mg/kg) was injected intravenously at 1 and 24 hr after the initiation of SAH in the prevention and reversal protocols, respectively. Behavioral changes were assessed at 48 hr after SAH. Protein expression was analyzed by Western blots. Results. Deficits in motor function were obvious in the SAH rats, and CGS 26303 significantly improved the rate of paraplegia. Expressions of rho-kinase-II and membrane-bound protein kinase C-and rhoA were significantly increased, while those of soluble guanylyl cyclase 1 and 1 as well as protein kinase G were significantly decreased in the basilar artery of SAH rats. Treatment with CGS 26303 nearly normalized these effects. Conclusions. These results demonstrate that the rhoA/rho-kinase and sGC/cGMP/PKG pathways play pivotal roles in cerebral vasospasm after SAH. It also shows that ECE inhibition is an effective strategy for the treatment of this disease.
Introduction
Subarachnoid hemorrhage (SAH) is an important subcategory of stroke due to an unacceptably high mortality rate as well as the severe complications it causes, such as cerebral vasospasm, neurological deficit, and cardiopulmonary abnormality [1] . The potent vasoconstrictor endothein-1 (ET-1) has been implicated in the pathogenesis of this disease [2] . One strategy to inhibit the biological effect of ET-1 is by means of its receptor antagonists. In fact, various selective and nonselective ET-1 receptor antagonists have been evaluated in animal models of cerebral vasospasm following SAH and in humans with varying degrees of success [3, 4] . An alternative approach to ameliorate the deleterious effects of ET-1 is to suppress the production of this vasoconstrictor by inhibiting endothelin-converting enzyme (ECE), which catalyzes the final step of ET-1 biosynthesis. CGS 26303 is such an inhibitor [5] [6] [7] [8] , and it has been shown to prevent and reverse cerebral vasospasm in a rabbit model of SAH [9] .
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The involvement of other vasoactive pathways downstream of ET-1 signaling in SAH is not completely understood. It has been shown that ET-1 potentiates the contraction of cerebrovascular smooth muscles induced by oxyhemoglobin, a blood clot component and major causative factor in cerebral vasospasm, via the protein kinase C (PKC) and rhoA/rho kinase pathways [11] . This is consistent with the finding that the PKC inhibitor staurosporine abolished ET-1-induced contraction in rabbit basilar artery [12] . In addition, lines of evidence accumulated to date have suggested that activation of protein kinase C (PKC) plays a role in the delayed and prolonged contraction of major arteries after SAH [13] [14] [15] . For example, phorbol 12,13-diacetate, a PKC activator, induced a potent and long-lasting contraction of the canine basilar artery [16] . In a two-hemorrhage canine model of cerebral vasospasm, translocation of PKC from the cytosol to membrane in the basilar artery was noted after the second injection of autologous blood on day 4 where severe vasospasm occurred, suggesting that this isoform of PKC was activated [17] . Furthermore, injection of the PKC inhibitor rottlerin into the cisterna magna on day 4 before the second hemorrhage inhibited this vasospastic response and PKC translocation [18] .
In contrast, the effect of elevated ET-1 in SAH on the rhokinase pathway has attracted less attention despite the documented involvement of rho-kinase in cerebral vasospasm following SAH [19, 20] . Rho is a family of small G-proteins consisting of 3 members, that is, rhoA, rhoB, and rhoC, that play a substantial role in intracellular signaling [10, 21] . Under unstimulated conditions, rho is in an inactive GDPbound form and resides mainly in the cytosol. In vascular smooth muscle cells stimulated by vasoactive agents, rho undergoes GDP-GTP exchange to become activated with a subsequent translocation to the cell membrane where it interacts with its downstream effectors such as rho-kinase (ROCK). There are two isoforms of rho-kinase, namely, ROCK-I and ROCK-II. Activation of rho-kinase promotes smooth muscle contraction by phosphorylation of myosin light chain phosphatase (MLCP) at the myosin-binding subunit, resulting in inhibition of the phosphatase activity [10, 21] . In a canine two-hemorrhage model of cerebral vasospasm, topical application of a specific inhibitor of rho-kinase Y-27632 dose-dependently decreased the spastic response, rho-kinase activity, and phosphorylation of MLCP in the basilar artery [22] .
Besides ET-1, the vasodilator nitric oxide (NO) produced by nitric oxide synthase in endothelium is also an important regulator of the cerebral vascular tone [23] . Upon synthesis, NO activates soluble guanylyl cyclase (sGC), a heterodimeric enzyme consisting of ( 1 , 2 , and 3 ) and ( 1 , 2 , and 3 ) subunits [24, 25] . Activation of sGC leads to the production of cGMP, which in turn activates cGMP-dependent protein kinase (PKG) among other targets and ultimately results in smooth muscle relaxation. Under physiological conditions, normal production of ET-1 and NO yields a balanced cerebral vascular tone. However, enhanced generation of ET-1 along with impairment in NO production or in the vasodilatory response to NO was noted in humans and animals with SAH [13] . Nevertheless, the effect of inhibition of ET-1 production on the sGC/cGMP pathway has not been fully investigated.
In the present study, we aimed to assess the neurological deficits, plasma ET-1 levels, and the expressions of PKC , rhoA, ROCK-II, and sGC/cGMP/PKG in the basilar artery of rats subjected to experimental SAH. The effect of CGS 26303 on the neurological deficits and vasoactive pathways downstream of ET-1 signaling in SAH was also investigated. 
Materials and Methods

Animal Protocols.
All animal procedures were approved by the Kaohsiung Medical University Hospital animal research committee. Thirty male Sprague-Dawley rats (BioLasco, Taiwan) weighing 250-300 g were divided into the following five groups ( = 6/group): Group 1, control animals (PBS); Group 2, rats subjected to SAH; Group 3, SAH rats treated with vehicle (0.1 mol/L NaOH/PBS); and Groups 4 and 5, SAH rats treated with CGS 26303 (10 mg/kg, i.v.) at 1 hr (prevention protocol) and 24 hr (reversal protocol) after SAH, respectively. To induce SAH, rats were anesthetized with a mixture of KetaVed (55 mg/kg) and xylazine (9 mg/kg) intraperitoneally (i.p.), and fresh blood (1 mL/kg) was drawn from the central tail artery and injected into the cistern magna according to a published protocol [8] . The mortality rate after induction of SAH was 15-20%, and it was the same in all of the SAH groups.
Hemodynamic Measurements.
Heart rate and blood pressure were monitored before and after CGS 26303 treatment as well as at 48 hr after the induction of SAH by a tail-cuff method.
Neurological Assessment.
Neurological assessment was performed before and at 48 hr after the induction of SAH. Motor function was quantified by assessment of ambulation and placing and stepping responses using a scoring system published previously and shown in Table 1 (a) [26] .
Determination of Plasma ET-1 and Tissue cGMP Levels.
Blood was collected in heparin-containing tubes prior to sacrifice. Plasma samples were frozen at −70 ∘ C until use. ET-1 was determined using an ELISA kit according to the Subarachnoid hemorrhage (SAH) was induced in rats by injecting autologous blood into the cisterna magna. CGS 26303 was administered intravenously at a dose of 10 mg/kg at 1 (prevention protocol, P) or 24 (reversal protocol, R) hr after SAH. The motor function was assessed using the scoring system shown in Table 1 (a) and was performed at 48 hr after SAH prior to sacrifice. Six animals were used in each group, and motor function assessment was performed five times for each animal. MDI is the sum of scores from ambulation and placing/stepping reflex. The paraplegia rate is defined as the percentage of rats with MDI ≥ 3 in each group ( = 6). * < 0.05 versus the SAH group.
instruction of the manufacturer. cGMP in the homogenate of basilar artery was measured by an ELISA kit.
Tissue Morphometry.
At 48 hr after the induction of SAH, the animals were anesthetized by chloral hydrate (0.3 mg/kg, i.p.). Perfusion-fixation was performed according to a published protocol [9] . Basilar arteries were harvested from the brainstems, and the middle third of each artery was dissected for morphometric analysis. The rest of tissue was frozen in liquid N 2 and stored at −70 ∘ C until use for measurements of protein expression and cGMP levels.
Protein Expression.
Basilar arteries were homogenized in buffers C, N, and M for extraction of cytoplasmic, nuclear, and membrane-bound proteins, respectively, according to the instructions of the manufacturer. Expressions of PKC , rhoA, ROCK-II, sGC 1 , sGC 1 , and PKG were determined by Western blots using specific antibodies according to the instructions of the respective manufacturers.
Statistical Analyses.
Group data are expressed as the means ± SEM. Comparison of the neurological deficit scores between groups was performed by the Mann-Whitney test.
Comparison of protein expression and biomarkers between groups was done using one-way ANOVA followed by Dunnett's test. Differences were considered significant at < 0.05.
Results
General Observations.
No statistically significant differences in the body weight, heart rate, or blood pressure were found among the 5 groups at the end of the experiments (results not shown). Visual inspection during the removal of the brain showed that subarachnoid clots had formed and covered the basilar artery in all animals subjected to SAH.
Neurological Deficit.
Using the scoring system shown in Table 1 (a), both the ambulation and placing/stepping reflex scores in the SAH and SAH+vehicle groups were significantly higher than in the controls (Table 1(b) ). The sum of scores from these two tests is referred to as motor deficit index (MDI). The values of MDI in the SAH and SAH+vehicle groups were 2.36±0.20 and 2.27±0.18, respectively, compared with a score of 0 in the normal control. Treatment with CGS 26303 significantly improved the MDI in the prevention and reversal groups (Table 1(b) ). Likewise, paraplegia rate (defined as the percentage of rats with MDI ≥ 3 in each group) was substantially decreased in both the CGS 26303 treatment groups when compared with the SAH animals (Table 1(b) ).
Plasma ET-1 Levels.
When compared with controls, plasma ET-1 levels in the SAH group were significantly elevated (Figure 1(a) ). Injection with CGS 26303 drastically decreased plasma ET-1 in both the prevention and reversal groups to levels that were not statistically different from the control.
Tissue Morphometry.
The internal elastic lamina in the basilar artery of SAH and SAH+vehicle groups showed substantial corrugation when compared with that obtained from controls (Figure 1(b) ). Corrugation was significantly less prominent in the SAH+CGS 26303 groups. The crosssectional areas of basilar artery in the SAH and SAH+vehicle groups were significantly reduced when compared with the control group. Treatment with CGS 26303 significantly attenuated the decrease in both the prevention and reversal groups (results not shown).
Translocation of PKC .
It has been shown that PKC translocates from the cytosolic compartment to become membrane-bound upon activation. The ratio of PKC membrane to cytosolic expression in the basilar artery of the SAH rats was set at 100% as a reference. Only about 60% of PKC was membrane-bound in normal animals, treated with CGS 26303 either at 1 or 24 hr after SAH inhibited the translocation of PKC to levels similar to that of the normal control (Figure 2 ).
RhoA Translocation and ROCK-II Expression in the Basilar
Artery. Similar to that seen with PKC , rhoA also translocates from the cytosolic compartment to become membrane-bound upon activation. In the basilar artery, membrane-bound rhoA was significantly greater in rats subjected to SAH when compared with the normal control (Figure 3(a) ). Treatment with vehicle had no effect, while CGS 26303 significantly reduced membrane-bound rhoA.
The pattern of ROCK-II expression in the basilar artery resembled that observed with levels of membranebound PKC or rhoA. ROCK-II expression was significantly increased in the SAH and SAH+vehicle groups when compared with controls, and treatment with CGS 26303 normalized the expression of ROCK-II (Figure 3(b) ).
Expression of sGC and Its Downstream cGMP/PKG Pathway in the Basilar Artery.
In contrast to an increased expression of ROCK-II in the basilar artery of rats subjected to SAH, the expressions of sGC 1 and sGC 1 were significantly decreased when compared with the controls (Figure 4 these two enzymes to levels that were not statistically different from the controls (Figure 4) .
Consistent with reduced expressions of sGC 1 and sGC 1 in the basilar artery of SAH rats, the levels of cGMP were also significantly decreased in these animals ( Figure 5(a) ). Administration of CGS 26303 in both the prevention and reversal protocols significantly attenuated the reduction of cGMP production in the basilar artery of the SAH animals ( Figure 5(a) ). This increased production of cGMP upon CGS 26303 treatment also resulted in an increased expression of PKG in the basilar artery of the SAH rats which, if untreated, showed a significant reduction in PKG expression when compared with the controls (Figure 5(b) ). 1 , and sGC 1 in the Brain, Heart, and Lung. It has been shown that ROCK and sGC have a wide distribution in the brain, especially in the cortex, hippocampus, and cerebellum [27, 28] . The expressions of ROCK-II, sGC 1 , and sGC 1 in these regions as well as in the brain stem were investigated. Furthermore, the expressions of these enzymes were examined in the heart and lung, since an increase in the levels of plasma ET-1 was found in the SAH rats and ET-1 was shown to play pathogenic roles in various cardiac and pulmonary diseases.
Expressions of ROCK-II, sGC
Unexpectedly, no significant changes in the expressions of ROCK-II, sGC 1 , and sGC 1 were found in these tissues examined in the SAH rats when compared with the control animals, except for an increased expression of ROCK-II in the heart (results not shown). Interestingly, no effects on the expressions of these enzymes were detected upon treatment with CGS 26303 in the SAH animals.
Discussion
Cerebral vasospasm following SAH is the leading cause of death and disability after aneurysm rupture. Despite the extensive research and numerous clinical studies conducted, the neurological outcomes in various trials for patients suffering from SAH remain disappointing [29] . Furthermore, assessment of neurological deficits in preclinical studies is scarce. In this regard, the results reported in the present study showing that an ECE inhibitor CGS 26303 significantly improved the motor function index and the rate of paraplegia in the SAH rats are significant findings. In addition, treatment with CGS 26303 decreased the activation of PKC and rhoA as well as the expression of rho-kinase, factors thought to contribute to the spastic response, while it concomitantly enhanced components in the sGC/cGMP/PKG pathway. These results suggest that the PKC, rhoA/rho-kinase, and sGC/cGMP/PKG pathways may play important roles in cerebral vasospasm after SAH and that the beneficial effects of CGS 26303 in cerebral vasospasm following SAH might be due to additive influence on all three pathways.
As described herein, the levels of plasma ET-1 were significantly increased with concomitant activation of the PKC and rhoA/rho kinase-II pathways in the basilar artery of rats subjected to SAH. Treatment with the ECE inhibitor CGS 26303 normalized plasma ET-1 as well as the expression of the two vasoconstrictive pathways. These results are consistent with the reports showing that oxyhemoglobin is a major causative component of blood clot for cerebral vasospasm following SAH [30, 31] and that ET-1 potentiates the oxyhemoglobin-induced cerebrovascular smooth muscle contraction via the rhoA/rho kinase and PKC pathways [11] . In the present study, the expression of rho kinase-II in the heart, but not in various regions of the brain and the lung, was also activated upon induction of SAH. Interestingly, the expression of ROCK-II in the heart appears to be ET-1-independent as treatment with CGS 26303 had no effect.
In contrast to the activation of the two aforementioned vasoconstrictive pathways, SAH resulted in decreased expression of the vasodilatory pathway sGC/cGMP/PKG ( Figures  4 and 5) . This pathway has been documented as NOmediated. However, in a previous study, neither neuronal nor endothelial NO synthase mRNA expression in the brain of the SAH rats was significantly different from that in the brain of the controls and treatment with CGS 26303 had no effect [32] . Nevertheless, it is worth noting that, in addition to its ECE inhibitory activity, CGS 26303 also inhibits the activity of neutral endopeptidase (NEP) [17, 33] , which degrades potent vasodilators such as atrial natriuretic peptide (ANP) [34] . In the present study it is possible that an elevated ANP level due to CGS 26303 treatment stimulates the sGC/cGMP/PKG pathway via increased production of NO through the inducible NO synthase as seen in the neonatal rat cardiac myocytes [35] . 
Conclusion
In summary, this study shows that CGS 26303 reduced the levels of plasma ET-1, improved the motor function index, decreased the activation of the vasoconstrictive PKC and rhoA/rho-kinase pathways, and activated the vasodilatory sGC/cGMP/PKG pathway in rats subjected to SAH. It is likely that this compound exerts these beneficial effects via its dual ECE/NEP inhibitory activities. However, confirmation of the utility of CGS 26303 for the treatment of cerebral vasospasm following SAH awaits future clinical studies.
